This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19-25 February 2023 and includes updates on the Earthquake in Türkiye and

Immediate health needs following earthquakes in Türkiye and Syria are mostly related to trauma and the disruption of healthcare, however, infectious disease threats may be

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 12-18 February 2023 and includes updates on the Earthquake in Türkiye and

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 5-11 February 2023 and includes updates on streptococcal infection, measles, COVID-19, influenza,

ECDC recommends that healthcare facilities maintain and strengthen infection prevention and control (IPC) measures, due to the high community transmission and co-circulation of respiratory viruses

High levels of community transmission and the co-circulation of respiratory viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza, respiratory syncytial virus (RSV)

This issue of the Communicable Disease Threats Report (CDTR) covers the period 30 January – 5 February 2023 and includes updates on COVID-19, diphtheriae, mpox,

This core protocol for ECDC studies of vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2 or with influenza, version 2.0, represents

This protocol presents a common methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating EU/EEA Member States.

This issue of the Communicable Disease Threats Report (CDTR) covers the period 23-29 January 2023 and includes updates on COVID-19, diphtheriae, influenza, chikungunya, dengue and

This issue of the Communicable Disease Threats Report (CDTR) covers the period 15-21 January 2023 and includes updates on COVID-19, diphtheriae, influenza, Mpox and Cholera.

According to the current ECDC assessment, there is moderate probability of XBB.1.5 becoming dominant in the EU/EEA and causing a substantial increase in the number